BioSpace News Archive

Conformis, Inc. announced results of a published study that investigated the characteristic shapes of knees to see if typical patient identifiers such as gender, body type, or ethnicity influence the shape of the knee joint.

bioMérieux a world leader in the field of in vitro diagnostics, announces that its BIOFIRE® Blood Culture Identification 2 (BCID2) Panel has received Health Canada approval.

Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced the presentation of data supporting the continued development of its lead therapeutic programs at Digestive Disease Week (DDW) 2022 in San Diego.

Travecta Therapeutics, Pte Ltd. today announced that Donald C. Manning , MD, PhD, Chief Medical Officer and Head of Research and Development, will present at the 2022 BIO International Convention occurring June 13-16, 2022 in San Diego, CA.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the appointment of Minetta Liu , M.D., as its new chief medical officer (CMO) of oncology.

FDA Accepts CSL Behring’s Biologics License Application for Etranacogene Dezaparvovec for Priority Review.

Eucure Biopharma, a wholly owned subsidiary of Biocytogen Pharmaceuticals ( Beijing ) Co., Ltd. (“Biocytogen”), today announced that it will present two posters at the 2022 ASCO Annual Meeting, taking place in Chicago, IL and virtually from June 3-7, 2022.

EVX-101 is a clinical-stage drug candidate currently being developed as an adjunctive treatment for when first-line antidepressants alone are inadequate.

Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company pioneering the development of stem cell-based delivery of oncolytic viruses, has been granted a new patent (No. US 11,285,194, Combination immunotherapy approach for treatment of cancer) by the U.S. Patent and Trademark Office (USPTO) related to its proprietary SuperNova (SNV) technology platform.

Horizon Therapeutics plc (Nasdaq: HZNP) today announced a series of data presentations during The EULAR 2022 European Congress of Rheumatology.